These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7990984)

  • 1. [Chemotherapy in metastasized breast carcinoma: intermittent or continuous?].
    Nortier JW; Rodenburg CJ; Slee PH; Blijham GH
    Ned Tijdschr Geneeskd; 1994 Nov; 138(48):2383-6. PubMed ID: 7990984
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized clinical trials, clinical use, and hope: what relationship?
    Rettig RA; Jacobson PD; Farquhar CM; Aubry WM
    J Clin Oncol; 2008 May; 26(13):2223-4. PubMed ID: 18445852
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
    Köstler WJ; Brodowicz T; Zielinski CC;
    J Natl Cancer Inst; 2010 Feb; 102(3):207; author reply 207-8. PubMed ID: 20054016
    [No Abstract]   [Full Text] [Related]  

  • 4. Is it time for some new approaches for treating advanced ovarian cancer?
    McGuire WP
    J Natl Cancer Inst; 2006 Aug; 98(15):1024-6. PubMed ID: 16882933
    [No Abstract]   [Full Text] [Related]  

  • 5. [High-dose chemotherapy with hematopoietic stem-cell support in breast cancer].
    Viens P; Maraninchi D
    Bull Cancer; 2001 Sep; 88(9):835-41. PubMed ID: 11604355
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose intensification and breast cancer.
    Khayat D; Antoine E
    Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():153-77. PubMed ID: 9210898
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy schedules: impact on treatment outcomes and quality of life.
    Tattersall MH
    Prog Clin Biol Res; 1990; 354B():241-9. PubMed ID: 2236171
    [No Abstract]   [Full Text] [Related]  

  • 8. [Significance of cytostatic drug dose in adjuvant chemotherapy of breast carcinoma].
    Thomssen C
    Geburtshilfe Frauenheilkd; 1996 Jul; 56(7):M102-5. PubMed ID: 8964443
    [No Abstract]   [Full Text] [Related]  

  • 9. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
    Conte PF; Guarneri V; Bruzzi P; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Mammoliti S; Carnino F; Giannessi P; Costantini M; Moyano A; Baldini E;
    Cancer; 2004 Aug; 101(4):704-12. PubMed ID: 15305399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematics and oncology: a match for life?
    Piccart-Gebhart MJ
    J Clin Oncol; 2003 Apr; 21(8):1425-8. PubMed ID: 12668653
    [No Abstract]   [Full Text] [Related]  

  • 11. Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.
    Di Leo A; Piccart MJ
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):27-32. PubMed ID: 10403471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the hormonal treatment of breast cancer.
    Boughey JC; Buzdar AU; Hunt KK
    Curr Probl Surg; 2008 Jan; 45(1):13-55. PubMed ID: 18206436
    [No Abstract]   [Full Text] [Related]  

  • 13. Second and third line chemotherapy in advanced breast cancer.
    Alexopoulos A; Rigatos G; Stavrinidis E; Stavrakakis J; Scartsilas C; Papacharalambous A
    J Chemother; 1989 Jul; 1(4 Suppl):1189-90. PubMed ID: 16312828
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
    Benson JR
    J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversible ovarian ablation or chemotherapy: are we ready for quality of life to guide adjuvant treatment decisions in breast cancer?
    Goodwin PJ
    J Clin Oncol; 2003 Dec; 21(24):4474-5. PubMed ID: 14610047
    [No Abstract]   [Full Text] [Related]  

  • 16. The best use of adjuvant chemotherapy: new drugs and new use of "old" drugs.
    Hudis C
    Breast; 2005 Dec; 14(6):570-5. PubMed ID: 16183287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dense adjuvant chemotherapy for primary breast cancer.
    Fornier M; Norton L
    Breast Cancer Res; 2005; 7(2):64-9. PubMed ID: 15743513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polychemotherapy versus monotherapy in metastatic breast carcinoma].
    Tanner J; Dunst J
    Strahlenther Onkol; 1999 Sep; 175(9):471. PubMed ID: 10518983
    [No Abstract]   [Full Text] [Related]  

  • 19. Platinum-based chemotherapy in metastatic breast cancer: current status.
    Decatris MP; Sundar S; O'Byrne KJ
    Cancer Treat Rev; 2004 Feb; 30(1):53-81. PubMed ID: 14766126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CALGB 78909: Phase III trial of intravenous zoledronic acid in the prevention of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure.
    Clin Adv Hematol Oncol; 2005 Feb; 3(2):105-6. PubMed ID: 16166977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.